{
    "Title": "Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy",
    "URL": "https://doi.org/10.1371/journal.pntd.0008583",
    "Published": "September 16, 2020",
    "Subject_Areas": [
        "Mycobacterium leprae",
        "Mouse models",
        "Leprosy",
        "Post-exposure prophylaxis",
        "Drug therapy",
        "Bacterial growth",
        "Drug administration",
        "Genetically modified animals"
    ],
    "Authors": {
        "Shannon M. Lenz": [
            "IHRC, Inc. Atlanta, Georgia, United States of America"
        ],
        "Jaymes H. Collins": [
            "Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, National Hansen\u2019s Disease Programs\u2013Laboratory Research Branch, Baton Rouge, Louisiana, United States of America"
        ],
        "Nashone A. Ray": [
            "Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, National Hansen\u2019s Disease Programs\u2013Laboratory Research Branch, Baton Rouge, Louisiana, United States of America"
        ],
        "Deanna A. Hagge": [
            "Mycobacterial Research Laboratories, Anandaban Hospital, The Leprosy Mission Nepal, Kathmandu, Nepal"
        ],
        "Ramanuj Lahiri": [
            "Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, National Hansen\u2019s Disease Programs\u2013Laboratory Research Branch, Baton Rouge, Louisiana, United States of America"
        ],
        "Linda B. Adams": [
            "Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, National Hansen\u2019s Disease Programs\u2013Laboratory Research Branch, Baton Rouge, Louisiana, United States of America"
        ]
    }
}